Gilead Sciences Inc. (NASDAQ:GILD) – Equities researchers at Leerink Swann dropped their Q3 2016 earnings estimates for Gilead Sciences in a research note issued on Friday. Leerink Swann analyst G. Porges now expects that the firm will post earnings per share of $2.81 for the quarter, down from their prior forecast of $2.91. Leerink Swann currently has a “Outperform” rating and a $112.00 price target on the stock.
Several other equities research analysts also recently issued reports on GILD. Zacks Investment Research downgraded Gilead Sciences from a “hold” rating to a “sell” rating in a report on Monday, June 13th. Jefferies Group reiterated a “hold” rating and issued a $96.00 price objective on shares of Gilead Sciences in a report on Sunday, June 12th. Morgan Stanley reiterated a “hold” rating and issued a $103.00 price objective on shares of Gilead Sciences in a report on Wednesday, June 15th. BMO Capital Markets reiterated an “outperform” rating and issued a $97.00 price objective on shares of Gilead Sciences in a report on Wednesday, June 29th. Finally, Credit Suisse Group AG reiterated a “buy” rating and issued a $120.00 price objective on shares of Gilead Sciences in a report on Wednesday, June 29th. Ten analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $104.71.
Gilead Sciences (NASDAQ:GILD) opened at 75.24 on Monday. The stock has a market capitalization of $99.29 billion, a PE ratio of 6.60 and a beta of 1.10. Gilead Sciences has a 52 week low of $74.92 and a 52 week high of $111.11. The stock has a 50 day moving average price of $78.95 and a 200 day moving average price of $85.05.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.02 by $0.06. Gilead Sciences had a return on equity of 106.75% and a net margin of 50.50%. The firm earned $7.78 billion during the quarter, compared to analysts’ expectations of $7.80 billion. During the same period last year, the business posted $3.15 earnings per share. The company’s revenue for the quarter was down 5.7% compared to the same quarter last year.
A number of large investors have recently made changes to their positions in GILD. BNP Paribas Arbitrage SA boosted its stake in shares of Gilead Sciences by 0.4% in the second quarter. BNP Paribas Arbitrage SA now owns 2,170,640 shares of the biopharmaceutical company’s stock worth $181,075,000 after buying an additional 8,430 shares during the period. Adage Capital Partners GP L.L.C. boosted its stake in shares of Gilead Sciences by 17.5% in the first quarter. Adage Capital Partners GP L.L.C. now owns 1,739,537 shares of the biopharmaceutical company’s stock worth $159,794,000 after buying an additional 258,807 shares during the period. Geode Capital Management LLC boosted its stake in shares of Gilead Sciences by 1.3% in the first quarter. Geode Capital Management LLC now owns 12,410,846 shares of the biopharmaceutical company’s stock worth $1,137,969,000 after buying an additional 161,505 shares during the period. Temasek Holdings Private Ltd boosted its stake in shares of Gilead Sciences by 8.1% in the first quarter. Temasek Holdings Private Ltd now owns 13,830,516 shares of the biopharmaceutical company’s stock worth $1,270,471,000 after buying an additional 1,035,592 shares during the period. Finally, Omega Advisors Inc. bought a new stake in shares of Gilead Sciences during the first quarter worth approximately $47,491,000. Hedge funds and other institutional investors own 77.94% of the company’s stock.
In other Gilead Sciences news, EVP Paul Rutherford Carter sold 2,000 shares of the stock in a transaction on Monday, August 1st. The stock was sold at an average price of $79.81, for a total transaction of $159,620.00. Following the sale, the executive vice president now owns 64,122 shares in the company, valued at approximately $5,117,576.82. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Kevin E. Lofton sold 3,500 shares of the stock in a transaction on Wednesday, August 24th. The shares were sold at an average price of $81.97, for a total value of $286,895.00. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.
The business also recently announced a quarterly dividend, which was paid on Thursday, September 29th. Shareholders of record on Friday, September 16th were issued a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 2.50%. The ex-dividend date was Wednesday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 16.56%.
About Gilead Sciences